Total Payments
$470.43
2024 Payments
$88.35
Companies
13
Transactions
20
Medicare Patients
3,015
Medicare Billing
$395,499
Payment Breakdown by Category
Food & Beverage$362.45 (77.0%)
Education$107.98 (23.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $362.45 | 12 | 77.0% |
| Education | $107.98 | 8 | 23.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic, Inc. | $142.28 | 1 | $0 (2022) |
| GENZYME CORPORATION | $55.83 | 2 | $0 (2023) |
| Seattle Genetics, Inc. | $49.16 | 4 | $0 (2019) |
| Stemline Therapeutics Inc. | $45.52 | 2 | $0 (2022) |
| ARRAY BIOPHARMA INC | $33.12 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $31.88 | 2 | $0 (2024) |
| Kite Pharma, Inc. | $21.05 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $18.44 | 1 | $0 (2020) |
| Merck Sharp & Dohme LLC | $18.09 | 1 | $0 (2024) |
| ABBVIE INC. | $17.18 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88.35 | 5 | ARRAY BIOPHARMA INC ($33.12) |
| 2023 | $90.15 | 4 | GENZYME CORPORATION ($55.83) |
| 2022 | $187.80 | 3 | Medtronic, Inc. ($142.28) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $18.44 | 1 | E.R. Squibb & Sons, L.L.C. ($18.44) |
| 2019 | $38.82 | 3 | Seattle Genetics, Inc. ($24.58) |
| 2018 | $24.58 | 2 | Seattle Genetics, Inc. ($24.58) |
| 2017 | $10.37 | 1 | Ipsen Biopharmaceuticals, Inc ($10.37) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.96 | General |
| 07/17/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: ONCOLOGY | ||||||
| 10/05/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: Oncology | ||||||
| 05/08/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $39.29 | General |
| Category: Oncology | ||||||
| 04/04/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $13.27 | General |
| Category: Oncology | ||||||
| 03/10/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $21.05 | General |
| 12/08/2022 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $31.52 | General |
| Category: Oncology | ||||||
| 12/07/2022 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Oncology | ||||||
| 06/10/2022 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $142.28 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 07/10/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $18.44 | General |
| Category: Oncology | ||||||
| 06/17/2019 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug), IDHIFA | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 02/07/2019 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 07/31/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 04/03/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 05/19/2017 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Education | In-kind items and services | $10.37 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 380 | 643 | $146,338 | $58,544 |
| 2022 | 7 | 392 | 772 | $169,459 | $79,724 |
| 2021 | 9 | 555 | 1,238 | $226,752 | $132,841 |
| 2020 | 23 | 1,688 | 3,302 | $244,157 | $124,390 |
Total Patients
3,015
Total Services
5,955
Medicare Billing
$395,499
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 128 | 241 | $63,816 | $26,717 | 41.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 156 | 280 | $53,860 | $20,931 | 38.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $9,792 | $3,283 | 33.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 27 | $6,939 | $2,679 | 38.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 43 | $5,332 | $2,562 | 48.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $5,715 | $2,062 | 36.1% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Facility | 2023 | 13 | 13 | $884.00 | $309.98 | 35.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 105 | 266 | $70,224 | $30,935 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 174 | 314 | $59,660 | $24,252 | 40.7% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2022 | 33 | 93 | $14,880 | $14,846 | 99.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $11,016 | $3,998 | 36.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 24 | 24 | $5,802 | $2,476 | 42.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 37 | $4,588 | $2,105 | 45.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 11 | 11 | $3,289 | $1,113 | 33.8% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 60 | 382 | $61,120 | $62,016 | 101.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 230 | 532 | $97,153 | $41,853 | 43.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 65 | 107 | $27,543 | $12,549 | 45.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 96 | 108 | $13,491 | $5,534 | 41.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 37 | 37 | $10,811 | $4,030 | 37.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $7,945 | $3,013 | 37.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 18 | 23 | $5,477 | $2,417 | 44.1% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 11 | 11 | $2,096 | $749.43 | 35.8% |
| 0003A | Fee covid-19 vac 1 booster | Facility | 2021 | 18 | 18 | $1,116 | $678.81 | 60.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 218 | 438 | $75,774 | $34,335 | 45.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 47 | 206 | $32,960 | $32,522 | 98.7% |
About Dr. Flavia Kostov, M.D
Dr. Flavia Kostov, M.D is a Hematology & Oncology healthcare provider based in Newport News, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1174545107.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Flavia Kostov, M.D has received a total of $470.43 in payments from pharmaceutical and medical device companies, with $88.35 received in 2024. These payments were reported across 20 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($362.45).
As a Medicare-enrolled provider, Kostov has provided services to 3,015 Medicare beneficiaries, totaling 5,955 services with total Medicare billing of $395,499. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Newport News, VA
- Active Since 07/25/2006
- Last Updated 01/20/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1174545107
Products in Payments
- INTELLIS ADAPTIVESTIM (Device) $142.28
- SARCLISA (Biological) $55.83
- ADCETRIS (Biological) $49.16
- ELZONRIS (Drug) $45.52
- LORBRENA (Drug) $19.50
- OPDIVO (Biological) $18.44
- KEYTRUDA (Biological) $18.09
- VENCLEXTA (Drug) $17.18
- TIBSOVO (Drug) $14.24
- BRAFTOVI (Drug) $13.62
- LUMAKRAS (Drug) $13.27
- Onivyde (Drug) $10.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Newport News
David Chang, M.d., Phd, M.D., PHD
Hematology & Oncology — Payments: $84,986
Hematology & Oncology $84,986
Bruce Booth, Md, MD
Hematology & Oncology — Payments: $21,024
Hematology & Oncology $21,024
Frankie Powell, Md, MD
Hematology & Oncology — Payments: $4,566
Hematology & Oncology $4,566
Dr. Ligeng Tian, B.m, B.M
Hematology & Oncology — Payments: $4,095
Hematology & Oncology $4,095
Mashour Yousef, M.d, M.D
Hematology & Oncology — Payments: $815.18
Hematology & Oncology $815.18
Vihitha Thota, Md, MD
Hematology & Oncology — Payments: $236.43
Hematology & Oncology $236.43